Allopurinol

Routes
Oral (PO)
Half-Life (t½)
PO: 2h
Formula
C5H4N4O
Molecular Weight
136.11 g/mol
PubChem CID
135401907
Aliases
Zyloprim

Pharmacological Mechanism

Xanthine oxidase inhibitor — converts to active oxipurinol; both compete with hypoxanthine + xanthine for XO active site. Lowers serum uric acid in gout + tumor lysis syndrome. SCAR (severe cutaneous adverse reactions) risk in HLA-B*5801 carriers (Asian / African ancestry).

Half-Life & Elimination Curve (PO: 2h)

100%50%25%12.5%0%0h0×t½2h1×t½4h2×t½6h3×t½8h4×t½10h5×t½0×t½ (0h): 100% remaining (~2.41 mg/L)1×t½ (2h): 50% remaining (~1.2 mg/L)2×t½ (4h): 25% remaining (~0.602 mg/L)3×t½ (6h): 12.5% remaining (~0.301 mg/L)4×t½ (8h): 6.3% remaining (~0.15 mg/L)5×t½ (10h): 3.1% remaining (~75.2 µg/L)
Plasma (PO)t½ Decay (2h)
  • 0×t½0h100% (2.41 mg/L)
  • 1×t½2h50% (1.2 mg/L)
  • 2×t½4h25% (0.602 mg/L)
  • 3×t½6h12.5% (0.301 mg/L)
  • 4×t½8h6.3% (0.15 mg/L)
  • 5×t½10h3.1% (75.2 µg/L)
Elimination t½2h (PO)
Rate Constant (ke)0.347 h⁻¹
Time to Peak (Tmax)1.27h
Est. Peak (Cmax)2.41 mg/L
Clearance (CL)22.5 L/h
97% Washout (5×t½)10h

Dosing Guidelines

Pharmacokinetic Parameters

Pathways It Modulates

Target Organ Systems

Chemical Structure & Identifiers